Helicos BioSciences Announces First "Early Access" Partnership with Institute for Systems Biology

Helicos BioSciences Corporation

Helicos BioSciences Announces First "Early Access" Partnership with Institute for Systems Biology

June 7, 2006

CAMBRIDGE, Mass.--(BUSINESS WIRE)--June 7, 2006--Helicos BioSciences, a pioneer in high-speed, high-sensitivity sequencing, today announced a new partnership with the Institute for Systems Biology (ISB) as the company's first "Early Access" program research collaborator. The ISB is an internationally renowned non-profit research institute dedicated to the study and application of systems biology. The partnership will allow the ISB access to Helicos' True Single Molecule Sequencing (tSMS(TM)) technology and protocols for use in its scientifically groundbreaking research projects. The tSMS(TM) technology enables researchers to rapidly and accurately sequence individual molecules of DNA and RNA and promises to provide both maximum efficiency and cost-savings.

"The Institute for Systems Biology is very excited to begin applying the capabilities of true single molecule sequencing technology in the area of cancer research. The tSMS(TM) technology will allow us to address questions in the field of oncology that have, up until this point, remained elusive," said Leroy Hood, president and co-founder of the Institute for Systems Biology.

"Helicos is pleased to have the prestigious Institute for Systems Biology as a research partner in the 'Early Access' program," said Stanley N. Lapidus, president and CEO of Helicos BioSciences. "While the promise of single molecule sequencing has drawn research attention and investment for almost two decades, we are finally at the point where its promise can begin to be realized. As pioneers in DNA and RNA sequencing and detection, Dr. Hood and his group represent an auspicious initial collaboration for our program, and for the application of tSMS(TM) in general. We look forward to a growing number of future partnerships with leading researchers worldwide."

About tSMS(TM)

tSMS(TM) is a technique that enables researchers to rapidly and accurately sequence individual molecules of DNA and RNA. This allows direct interrogation of the single molecule as opposed to an amplified population of molecules. tSMS(TM) holds enormous potential for elucidating the gamut of genetic aberrations in oncology, through the ability to serve as a universal detection system across a wide variety of applications for both DNA and RNA.

An example of some of the applications tSMS(TM) will enable are whole tumor resequencing, quantitative transcriptional profiling, genome wide methylation studies, and candidate gene resequencing.

The advantages of tSMS(TM) over amplified molecule sequencing include: no PCR bias, no errors introduced by amplification, and no dephasing issues commonly present in amplified molecule sequencing. In addition, tSMS(TM) promises the highest possible throughput and enables reagent cost savings on the order of 1,000 times less than Sanger sequencing.

About the Institute for Systems Biology

The Institute for Systems Biology (ISB) is an internationally renowned non-profit research institute dedicated to the study and application of systems biology. ISB's goal is to unravel the mysteries of human biology and identify strategies for predicting and preventing diseases such as cancer, diabetes and AIDS. The driving force behind the innovative "systems" approach is the integration of biology, computation, and technology. This approach allows scientists to analyze all of the elements in a system rather than one gene or protein at a time. Located in Seattle, Washington, the Institute has grown to 11 faculty and more than 170 staff members; an annual budget of more than $25 million; and an extensive network of academic and industrial partners. For more information about the ISB visit: www.systemsbiology.org

About Helicos BioSciences

Helicos BioSciences Corporation began operations in February 2004, after raising $27 million from a top-tier investment consortium. Helicos is developing instruments and reagents for the high-speed sequencing of DNA and RNA with the highest possible sensitivity. The Helicos technology, based on pioneering research of Dr. Stephen Quake of Stanford University, is covered by a broad portfolio of granted and filed patents. The company commenced early access collaborations in 2006 to generate groundbreaking scientific publications and start creating revenue, while planning to launch its first commercial systems in 2007.

For more information, please visit our web site at www.helicosbio.com.

Contacts

Aviator PR
Mario Fante, 617-763-9887
mario@aviator-pr.com